Navigation Links
EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
Date:5/13/2008

ROCKVILLE, Md., May 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S. Burns, President and Chief Executive Officer, will present a Company overview at the Rodman and Renshaw 5th Annual Global Healthcare Conference, to be held at the Le Meridien Beach Plaza Hotel in Monte Carlo, May 19-20, 2008. Mr. Burns' presentation is scheduled for Monday, May 19, 2008 at 10:25 a.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

As previously mentioned, Mr. Burns' live presentation will be web cast and will serve as the Company's first quarter 2008 update. The presentation can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

CONTACT:

Ginny Dunn

Associate Director

Corporate Communications &Investor Relations

EntreMed, Inc.

240-864-2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. EntreMed Reports First Quarter 2008 Financial Results
2. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
3. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
4. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
5. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
6. EntreMed Reports Third Quarter 2007 Financial Results
7. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
8. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
9. EntreMed to Present at the Bio 2007 Investor Forum
10. EntreMed Receives Deloitte Technology Fast 50 Award
11. Emphasys Medical to Present VENT Clinical Trial Data at ATS 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... 17, 2017 , ... Park Cities Pet Sitter President, Joette White, has been ... Radio network. The episode, which was posted this week, features a 30-minute interview ... to Park Cities Pet Sitter’s being awarded the 2017 National Association of Professional Pet ...
(Date:2/18/2017)... ... February 18, 2017 , ... A new directory ... contact points to easily connect elderly veterans of America's armed forces to a ... It also conveys material on this year's increase in the Veterans Pension with ...
(Date:2/17/2017)... ... February 17, 2017 , ... While EHR data has ... introduced an innovative workstation designed to reduce nursing fatigue while enhancing productivity. Based ... Workstation offers a lightweight, highly mobile, multi-functional alternative to the limitations of handheld ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... that allow for the electronic prescribing of controlled and non-controlled substances plus the ... percent of pharmacies in the United States now accept electronic prescriptions, according to ...
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... ... ... to Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. ... , What are the critical reimbursement questions manufacturers should be asking ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , Feb 17, 2017 Research and Markets has ... Business Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , and Rest of World. Annual ... a six-year historic analysis is provided for these markets. Market data and ...
(Date:2/17/2017)... , Feb. 17, 2017   Risperdal lawsuits ... effects allegedly associated with use of the atypical antipsychotic ... Philadelphia Court of Common Pleas, where the ... tort program. According to a notice posted on the ... convene a meeting on March 9, 2017 at 11:00 ...
(Date:2/17/2017)... 17, 2017   FormFast , the leader in ... partnership with Engage , one of the largest ... . FormFast will serve as the forms automation and ... MEDITECH .  FormFast is a ... complement and enhance the electronic health record. FormFast,s technology ...
Breaking Medicine Technology: